...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New shares issued?

narmac - Since the first royalty is 2 to 3 years away why would DM want the hassles that go along with a public company. The individual molecules or groups of molecules can be sold off while we wait for apabetalone to start producing royalties if it even gets approved. The most value would be generated from ZCC when sales are reaching a targeted market penetration rate which I believe was in the 3rd to 5th year of sales. If it goes to the 5th year there may even be sales from ZEN3694 to add to the royalty pool that would add even more value. Personally I'm quite happy waiting for a number of years for ZCC to go public...if ever.

tada

Share
New Message
Please login to post a reply